Familial hypercholesterolemia
Drug research and approvals for familial hypercholesterolemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 43 studies of familial hypercholesterolemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 32 drug trials for it since 2013, and FDA has 12 approved and 12 open orphan designations naming it.
- Recruiting worldwide: 43
- Trials authorized in Canada: 32
- FDA orphan approvals: 12
- EU medicines: 0
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseNCT07839936 · Phase 2 · Eli Lilly and Company · starts Sep 24, 2026
- Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat…NCT07614958 · Phase 3 · A. Menarini International Licensing S.A. · starts May 6, 2026
- Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous…NCT07591298 · Phase 2 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · starts May 24, 2026
- A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and AlirocumabNCT07543731 · Not reported · Novartis Pharmaceuticals · starts Apr 2, 2026
- A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasNCT07491172 · Phase 1 · CRISPR Therapeutics AG · starts Jun 21, 2024
- A Dose-exploration Study of EDP167 in HoFHNCT07489209 · Phase 2 · Eddingpharm (Zhuhai) Co., Ltd. · starts Feb 6, 2026
- Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaNCT07473843 · Phase 3 · Arrowhead Pharmaceuticals · starts Oct 1, 2026
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular EventsNCT07474649 · Phase 3 · Daiichi Sankyo · starts Sep 14, 2026
- The ORIGIN-FH StudyNCT07470723 · Not applicable · University of Wisconsin, Madison · starts Feb 14, 2026
How its trials ended
241 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 75 whose ending is known, 69% met their primary endpoint, 5% missed it and 25% stopped early.
- Completed, result not reported7732%
- Ongoing6427%
- Met its primary endpoint5222%
- Status unknown2510%
- Stopped: other or unclear146%
- Missed its primary endpoint42%
- Stopped: lack of efficacy31%
- Stopped: enrollment or feasibility1<1%
- Stopped: sponsor or business decision1<1%
| Aug 7, 2026 | An operationally seamless phase 2/3 study to evaluate the safety, efficacy, and pharmacokinetics of enlicitide decanoate in pediatric participants with…Enlicitide (MK-0616) | Merck & Co. (MSD) | Pending |
| Oct 8, 2025 | Phase 3 study to evaluate the efficacy and safety of zodasiran in adolescent and adult subjects with homozygous familial hypercholesterolemia (yosemite)Zodasiran (ARO-ANG3, ADS-004) | Arrowhead Pharmaceuticals, Inc. | Ongoing |
| May 16, 2025 | A phase III, randomised, double-blind, placebo-controlled, parallel-group study to assess the effect of AZD0780 on low-density lipoprotein cholesterol in…Laroprovstat (AZD0780) | AstraZeneca Pharmaceuticals | Ongoing |
| Feb 22, 2024 | Open-label, phase lb, single ascending dose study to evaluate the safety of VERVE-102 administered to patients with heterozygous familial hypercholesterolemia…VERVE-102 | Verve Therapeutics | Ongoing |
| Jun 28, 2023 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mk¿0616 in adults with heterozygous familial…Enlicitide decanoate (MK-0616) | Merck & Co. (MSD) | Closed |
| Feb 10, 2023 | Safety and effectiveness of evinacumab for the treatment of homozygous familial hypercholesterolemia in a real life setting in canadaEvkeeza (evinacumab (REGN1500)) | Ecogene-21 | Ongoing |
| Dec 13, 2022 | An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or…Inclisiran (KJX839) | Novartis Pharmaceuticals | Ongoing |
| Aug 17, 2022 | An open-label study to evaluate the pharmacokinetics, pharmacodynamics, and safety of bempedoic acid in pediatric patients (6 to 17 years of age) with…Bempedoic acid | Esperion Therapeutics | Closed |
| Jan 13, 2022 | Phase 2 study to evaluate the safety and efficacy of ARO-ANG3 in subjects with homozygous familial hypercholesterolemia (HOFH)Zodasiran (ARO-ANG3, ADS-004) | Arrowhead Pharmaceuticals, Inc. | Closed |
| Jul 16, 2021 | Randomized, double-blind, placebo-controlled, phase 3 study to evaluate the long-term efficacy and safety of LIB003 in heterozygous familial…LIB003 | Lib Therapeutic LLC | Closed |
| Feb 12, 2026 | LeqvioAs an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in pediatric patients aged 12 years and older with… | Novartis Pharmaceuticals Corporation | Approved |
| Oct 9, 2025 | PraluentAs an adjunct to diet and exercise to reduce low- density lipoprotein cholesterol (LDL-C) in adults with homozygous familial… | Regeneron Pharmaceuticals, Inc. | Approved |
| Sep 25, 2025 | EvkeezaAs an adjunct to diet and exercise and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies to reduce LDL-C in adults and… | Regeneron Pharmaceuticals, Inc. | Approved |
| Aug 21, 2025 | RepathaAs an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults and pediatric patients aged 10 years and… | Amgen Inc. | Approved |
| Mar 21, 2023 | EvkeezaAs an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients,… | Regeneron Pharmaceuticals, Inc. | Approved |
| Sep 24, 2021 | RepathaAs an adjunct to other low-density lipoprotein cholesterol (LDL-C)-lowering therapies in adults and pediatric patients aged 10 years and… | Amgen Inc. | Approved |
| Apr 1, 2021 | PraluentAs an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C | Regeneron Pharmaceuticals, Inc. | Approved |
| Feb 11, 2021 | EvkeezaAdjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12… | Regeneron Pharmaceuticals, Inc. | Approved |
| May 27, 2016 | CrestorAn adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial… | iPR Pharmaceuticals, Inc. | Approved |
| Aug 27, 2015 | RepathaAs an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require… | Amgen Inc. | Approved |
| Jan 29, 2013 | KynamroAdjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total… | Kastle Therapeutics, LLC | Approved |
| Dec 21, 2012 | JuxtapidAdjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein… | Chiesi Farmaceutici S.p.A. | Approved |
| Sep 11, 2026 | Messenger RNA encoding for adenine base editor protein and…Treatment of homozygous familial hypercholesterolemia | Verve Therapeutics, a Wholly Owned Subs of Eli Lilly and Co | Designated |
| Aug 14, 2025 | Recombinant adeno-associated virus serotype 8 vector…Treatment of homozygous familial hypercholesterolemia | Nggt Inc. | Designated |
| May 15, 2025 | mRNA encoding the cholesterol degrading platform (CDP)…Treatment of homozygous familial hypercholesterolemia (HoFH) | Repair Biotechnologies, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA